Additionally, reducing caspase-6 aspartic acid concentrations can significantly enhance AMPK levels, inhibiting the progression of NAFLD cell death (Liang et al., 2021). Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.